New pages
- 23:03, 15 November 2019 Zanubrutinib (Brukinsa) (hist) [1,267 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: BTK inhibitor <br>Route: PO <br>Extravasation: n/a For conciseness and simplicity, HemOnc.org currently will focus on treatment regim...")
- 12:36, 14 November 2019 Antimicrobial prophylaxis (hist) [1,088 bytes] Jwarner (talk | contribs) (Created page with "This is a stub page that will be expanded over time =Guidelines= ==ASCO/IDSA== * '''2018:''' Taplitz et al. [https://ascopubs.org/doi/full/10.1200/JCO.18.00374 Antimicrobial...")
- 07:30, 8 November 2019 Experimental design (hist) [3,607 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor''' |- |s...")
- 18:57, 6 November 2019 Colon cancer, Her2-amplified (hist) [8,111 bytes] Ryannguyen (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")
- 21:12, 2 November 2019 Smoldering multiple myeloma (hist) [16,948 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26" |'''Page editor''' ! col...")
- 10:40, 14 October 2019 T-cell prolymphocytic leukemia (hist) [1,500 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' |- |s...")
- 20:40, 11 October 2019 Value frameworks (hist) [3,106 bytes] Jwarner (talk | contribs) (Created page with " =Introduction= Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combi...")
- 20:31, 1 October 2019 Trastuzumab-qyyp (Trazimera) (hist) [2,104 bytes] Jwarner (talk | contribs) (Created page with "'''Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.''' ==General informatio...")
- 20:30, 1 October 2019 Trastuzumab-dttb (Ontruzant) (hist) [2,104 bytes] Jwarner (talk | contribs) (Created page with "'''Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.''' ==General informatio...")
- 20:29, 1 October 2019 Trastuzumab-anns (Kanjinti) (hist) [2,103 bytes] Jwarner (talk | contribs) (Created page with "'''Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.''' ==General informatio...")
- 20:23, 1 October 2019 Rituximab-pvvr (Ruxience) (hist) [5,346 bytes] Jwarner (talk | contribs) (Created page with "'''Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.''' ==General...")
